News for Healthier Living

Daraxonrasib Demonstrates Initial Antitumor Activity in RAS-Mutant Lung Cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

September 2, 2026


September 3 2026

September 2 2026

September 1 2026

August 31 2026

August 30 2026

August 29 2026

August 28 2026

August 27 2026

August 26 2026

August 25 2026

August 24 2026

August 21 2026

August 20 2026